红细胞生成素在肾纤维化中的作用及机制研究  

The effects of erythropoietin on renal fibrosis

作　　者：张祥 陈红波[2] ZHANG Xiang;CHEN hong-bo(The First Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;The first affiliated hospital,Zhejiang Provincial Hospital of Traditional Chinese Medicine,Hangzhou 310006,China)

机构地区：[1]浙江中医药大学第一临床医学院,杭州310053 [2]浙江中医药大学附属第一医院肾病科,杭州310006

出　　处：《中国血液净化》2022年第7期465-468,共4页Chinese Journal of Blood Purification

基　　金：浙江省自然科学基金(LY18H290005)。

摘　　要：肾纤维化是大多数慢性肾脏病(chronic kidney disease,CKD)进展至终末期的共同病理表现,其严重程度与CKD的预后密切相关。近年来,相关研究发现红细胞生成素(erythropoietin,EPO)与肾纤维化的发生发展关系密切。EPO作为一种红细胞刺激因子,外源性补充EPO不仅可以治疗肾性贫血,还可以有效防治肾纤维化,从而改善肾功能。本文将EPO在肾纤维化中的作用及可能的抗纤维化作用机制进行综述,以期为防治肾纤维化提供新的治疗思路。Renal fibrosis is a common end-stage pathological manifestation of chronic kidney disease(CKD),and its severity is closely related to the prognosis of CKD.In recent years,some studies have found that erythropoietin(EPO)is closely associated with the occurrence and development of renal fibrosis.As a regulator of red blood cell production,exogenous EPO supplementation can not only improve renal anemia,but also improve renal function and effectively prevent and treat renal fibrosis.Therefore,this paper reviews the role of EPO in renal fibrosis and its anti-fibrosis mechanism,providing new ideas for the application of EPO in the treatment of renal fibrosis in the future.

关 键 词：红细胞生成素 肾纤维化 REP细胞 红细胞生成素受体 

分 类 号：R692.5[医药卫生—泌尿科学]